{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:41:45Z","timestamp":1780051305602,"version":"3.53.1"},"reference-count":51,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Introduction: During pharmaceutical care, community pharmacists play a crucial role by carrying out interventions aimed at preventing, detecting, and resolving drug-related problems (DRPs) and negative outcomes associated with medication (NOM), simultaneously enhancing patients\u2019 knowledge about their treatments. The chronic use of Benzodiazepines (BZDs) is known to be associated with risks such as tolerance, dependence, and cognitive impairment. Furthermore, the combined use of BZDs with other medications or alcohol may expose patients to significant drug interactions. Objectives: This study aimed to characterize and describe the clinical profile of patients using BZDs, to evaluate the extent of polypharmacy and potential drug interactions, to investigate their level of knowledge regarding BZD treatment, and ultimately, to propose evidence-based interventions from the community pharmacy to contribute to improving patient safety and minimizing risks associated with BZD use. Method: A cross-sectional, descriptive study was conducted in a single community pharmacy in Gran Canaria (Canary Islands, Spain). The study population comprised 125 adult patients with active BZD prescriptions. Data collection was performed through pharmacist\u2013patient structured interviews using a questionnaire that included sociodemographic, clinical, and BZD knowledge variables. Results: Lormetazepam and alprazolam were the BZDs most frequently prescribed and dispensed. Potential drug interactions with other medications were detected in 38.4% of BZD users. Notably, 61.5% of patients using BZDs also reported the concurrent use of opioid analgesics, with tramadol being the most common opioid (48.1% of BZD users were also treated with tramadol). Statistically significant differences were observed between patients with and without BZD and other drug interactions in several adverse outcome variables, including the risk of falls (p = 0.003), cognitive impairment (p = 0.047), and urinary incontinence (p = 0.016). Existing BZD dependence is detected in 25% and 22.1% of cases, respectively. Patients\u2019 knowledge of their BZD treatment revealed critical gaps, which are identified as a challenge and a clear opportunity for intervention through pharmaceutical care services. Conclusions: The findings underscore the essential and proactive role of community pharmacists in identifying and managing drug interactions, as well as in supporting deprescribing strategies through collaborative and interprofessional care models.<\/jats:p>","DOI":"10.3390\/pharmacy13060181","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T15:43:43Z","timestamp":1765467823000},"page":"181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6877-9734","authenticated-orcid":false,"given":"Juan Ram\u00f3n","family":"Santana Ayala","sequence":"first","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"},{"name":"Community Pharmacy (Farmacia Lcdo. Juan Ram\u00f3n Santana Ayala), Av. Guillermo Santana Rivero 13, 35012 Las Palmas de Gran Canaria, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-7405","authenticated-orcid":false,"given":"Daida","family":"Alberto Armas","sequence":"additional","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"},{"name":"Community Pharmacy (Farmacia Lcdo. Juan Ram\u00f3n Santana Ayala), Av. Guillermo Santana Rivero 13, 35012 Las Palmas de Gran Canaria, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-4850","authenticated-orcid":false,"given":"Veronica","family":"Hern\u00e1ndez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"},{"name":"Community Pharmacy (Farmacia Lcdo. Juan Ram\u00f3n Santana Ayala), Av. Guillermo Santana Rivero 13, 35012 Las Palmas de Gran Canaria, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-4993","authenticated-orcid":false,"given":"Armando","family":"Aguirre-Jaime","sequence":"additional","affiliation":[{"name":"Independent Biostatistician, 38001 Santa Cruz de Tenerife, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1581-0850","authenticated-orcid":false,"given":"\u00c1ngel J.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Paz-Montelongo","sequence":"additional","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Hardisson de la Torre","sequence":"additional","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-5870","authenticated-orcid":false,"given":"Carmen","family":"Rubio Armend\u00e1riz","sequence":"additional","affiliation":[{"name":"Environmental Toxicology and Food and Drug Safety Research Group, La Laguna University, 38071 La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","unstructured":"Bertram, G., and Katzung, M.D. (2019). Farmacolog\u00eda B\u00e1sica y Cl\u00ednica, McGraw Hill."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000524400","article-title":"Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice","volume":"91","author":"Dubovsky","year":"2022","journal-title":"Psychother. Psychosom."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shade, K.N., Ritvo, A.D., Silvernail, B., Finlayson, A.J.R., Bressi, J.E., Foster, D.E., Martin, I.J., Piper, C., and Martin, P.R. (2025). Long-term neurological consequences following benzodiazepine exposure: A scoping review. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0330277"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alberto Armas, D., Hern\u00e1ndez Garc\u00eda, V., Rom\u00e1n Castillo, Y., Santana Ayala, J.R., Capdevila Finestres, F., Hardisson de la Torre, A., and Rubio Armend\u00e1riz, C. (2024). Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service. Pharmacy, 12.","DOI":"10.3390\/pharmacy12040120"},{"key":"ref_5","first-page":"e53252","article-title":"Benzodiazepine Consumption, Functionality, Cognition, and Somnolence in Older Adults at a Tertiary Care Psychiatric Hospital in Mexico City","volume":"16","year":"2024","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40266-024-01144-7","article-title":"Fall Outcomes in Older Adults Following Benzodiazepine\/Z-Drug Discontinuation: A Retrospective Cohort Study in an Academic Health System","volume":"41","author":"Schindler","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Brunner, E., Chen, C.A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K.F., and Roll, E. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. J. Gen. Intern. Med., Ahead of print.","DOI":"10.1007\/s11606-025-09499-2"},{"key":"ref_8","unstructured":"Organizaci\u00f3n Mundial de la Salud (2021). Uso de Benzodiacepinas en Salud Mental, OMS. Available online: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/anxiety-disorders."},{"key":"ref_9","unstructured":"Ministerio de Sanidad de Espa\u00f1a (2025, September 08). Reporte de Consumo de BZD en Poblaci\u00f3n Adulta, Available online: https:\/\/pnsd.sanidad.gob.es\/profesionales\/sistemasInformacion\/informesEstadisticas\/pdf\/2022OEDA-INFORME.pdf."},{"key":"ref_10","unstructured":"European Union Drugs Agency (EUDA) (2023). Spotlight on Non-Medical Use of Benzodiazepines, EUDA. Available online: https:\/\/www.euda.europa.eu\/spotlights\/non-medical-use-benzodiazepines_en."},{"key":"ref_11","unstructured":"Junta Internacional de Fiscalizaci\u00f3n de Estupefacientes (2019). Informe Anual 2019, INCB. Available online: https:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2019\/Annual_Report\/Spanish_ebook_AR2019.pdf."},{"key":"ref_12","unstructured":"Socidrogalcohol, FAECAP, SEFAC, SEMERGEN, semFYC, and SEMG (2019). Gu\u00eda de Consenso Para el Buen Uso de las Benzodiacepinas: Gesti\u00f3n de Riesgos y Beneficios, Socidrogalcohol. [2nd ed.]. Available online: https:\/\/socidrogalcohol.org\/wp-content\/uploads\/2021\/04\/GUIA_Buen_Uso_Benzodiazepinas_Digital.pdf."},{"key":"ref_13","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2024). Informe Anual Sobre Consumo de Benzodiazepinas, AEMPS. Available online: https:\/\/app.powerbi.com\/view?r=eyJrIjoiMTcyODZlYWItNWE2ZS00YmYzLWE1MDktZDY2OWM2NmMyOTc3IiwidCI6IjJkM2I1MGUwLTZlZjQtNGViYy05MjQ2LTdkMWNiYjc3MDg5YyIsImMiOjh9."},{"key":"ref_14","unstructured":"Riera, E. (2025, September 08). Pharmacists. Noticias. 26 March 2024. Available online: https:\/\/www.univadis.es\/news\/all\/pharmacists."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jeong, H.E., Jeon, H.L., Oh, I.S., Kim, W.J., and Shin, J.Y. (2020). Risk of mortality associated with concomitant antidepressant and benzodiazepine therapy among patients with depression: A population-based cohort study. BMC Med., 18.","DOI":"10.1186\/s12916-020-01854-w"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.21037\/apm.2019.12.09","article-title":"Combining opioids and benzodiazepines: Effects on mortality and severe adverse respiratory events","volume":"9","author":"Boon","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"ref_17","first-page":"103","article-title":"Riesgos asociados al uso de Benzodiazepinas","volume":"31","author":"Danza","year":"2009","journal-title":"Arch. Med. Intern."},{"key":"ref_18","unstructured":"Fl\u00f3rez, J. (2014). F\u00e1rmacos ansiol\u00edticos y sedantes. Farmacolog\u00eda de los trastornos del sue\u00f1o. Farmacolog\u00eda Humana, Elsevier Masson. [6th ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/21501319221147378","article-title":"Sedative-hypnotic Co-prescribing with Opioids in a Large Network of Community Health Centers","volume":"14","author":"Hartung","year":"2023","journal-title":"J. Prim. Care Community Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40266-023-01071-z","article-title":"Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing","volume":"40","author":"Kelley","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hestevik, C.H., Evensen, L.H., Korn\u00f8r, H., and Skeie, I. (2024). The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: A systematic review. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-06191-3"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.sapharm.2022.12.009","article-title":"Identifying health outcomes of pharmaceutical clinical services in patients with cancer: A systematic review","volume":"19","author":"Carvalho","year":"2023","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_23","unstructured":"(2023, June 02). PCNE Classification for Drug-Related Problems V9.1. Available online: https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40266-023-01064-y","article-title":"Systematic Review and Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults: An Update","volume":"40","author":"Gray","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Szilvay, A., Somogyi, O., Dobszay, A., Mesk\u00f3, A., Zelk\u00f3, R., and Hank\u00f3, B. (2021). Analysis of interaction risks of patients with polypharmacy and the pharmacist interventions performed to solve them\u2014A multicenter descriptive study according to medication reviews in Hungarian community pharmacies. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253645"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1077558712459215","article-title":"Theeffectof community pharmacy-based interventions on patient health outcomes: A systematic review","volume":"70","author":"Blalock","year":"2013","journal-title":"Med. Care Res. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.sapharm.2022.10.007","article-title":"Community pharmacy and primary health care\u2014Types of integration and their applicability: A narrative review","volume":"19","author":"Gastelurrutia","year":"2023","journal-title":"Res. Social. Adm. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/pharmacy11040124","article-title":"What Are the Drug-Related Problems Still Faced by Patients in Daily Life?\u2014A Qualitative Analysis at the Pharmacy Counter","volume":"11","author":"Kaae","year":"2023","journal-title":"Pharmacy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.sapharm.2022.12.002","article-title":"A community pharmacy practice-based research network: A protocol for a realist evaluation","volume":"19","author":"Handyside","year":"2022","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_30","unstructured":"CGCOF (Consejo General de Colegios Oficiales de Farmac\u00e9uticos) (2025, November 11). BOT Plus. Available online: https:\/\/www.farmaceuticos.com\/botplus\/que-es-botplus\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-W","article-title":"The Benzodiazepine Withdrawal Symptom Questionnaire","volume":"19","author":"Tyrer","year":"1990","journal-title":"J. Affect. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wu, C.C., Liao, M.H., Su, C.H., Poly, T.N., and Lin, M.C. (2023). Benzodiazepine Use and the Risk of Dementia in the Elderly Population: An Umbrella Review of Meta-Analyses. J. Pers. Med., 13.","DOI":"10.3390\/jpm13101485"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.18773\/austprescr.2022.031","article-title":"The anticholinergic burden: From research to practice","volume":"45","author":"Hilmer","year":"2022","journal-title":"Aust. Prescr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0376-8716(84)90001-2","article-title":"Effects of combined alcohol and benzodiazepine: A review","volume":"13","author":"Chan","year":"1984","journal-title":"Drug Alcohol Depend."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1300\/J251v03n04_03","article-title":"Alcohol interactions with benzodiazepines and cocaine","volume":"3","author":"Hoyumpa","year":"1984","journal-title":"Adv. Alcohol. Subst. Abus."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/pds.1702","article-title":"Alcohol consumption among Canadians taking benzodiazepines and related drugs","volume":"18","author":"Veldhuizen","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_38","first-page":"233","article-title":"Interactions between alcohol and benzodiazepines","volume":"8","author":"Hollister","year":"1990","journal-title":"Recent Dev. Alcohol."},{"key":"ref_39","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Burato, S., Leonardi, L., Antonazzo, I.C., Raschi, E., Ajolfi, C., Baraghini, M., Chiarello, A., Delmonte, V., Di Castri, L., and Donati, M. (2021). Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.624888"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Maust, D.T., Bohnert, A.S.B., Strominger, J., Alexander, N., Min, L., Hoffman, G.J., and Goldstick, J.E. (2022). Prescription characteristics associated with fall-related injury risk among older adults prescribed benzodiazepines: A cohort study. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03497-3"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Valle, J., Correia, R.B., Camacho-Artacho, M., Lepore, R., Mattos, M.M., Rocha, L.M., and Valencia, A. (2024). Prevalence and differences in the co-administration of drugs known to interact: An analysis of three distinct and large populations. BMC Med., 22.","DOI":"10.1186\/s12916-024-03384-1"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.aprim.2021.102041","article-title":"Calidad de vida relacionada con la salud en pacientes consumidores de benzodiacepinas [Health-related quality of life in patients consuming benzodiazepine]","volume":"53","year":"2021","journal-title":"Atenci\u00f3n Primaria"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Huff, C., Finlayson, A.J.R., Foster, D.E., and Martin, P.R. (2023). Enduring neurological sequelae of benzodiazepine use: An Internet survey. Ther. Adv. Psychopharmacol., 13.","DOI":"10.1177\/20451253221145561"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.11606\/s1518-8787.2021055003103","article-title":"Skills and practices of pharmacy staff for dispensing of drugs with fiscalized substances in drugstores and pharmacies","volume":"55","author":"Ceballos","year":"2021","journal-title":"Rev. Saude Publica"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Buhl, C., Olsen, N.L., N\u00f8rgaard, L.S., Thomsen, L.A., and Jacobsen, R. (2023). Community Pharmacy Staff\u2019s Knowledge, Educational Needs, and Barriers Related to Counseling Cancer Patients and Cancer Survivors in Denmark. Int. J. Environ. Res. Public Heal., 20.","DOI":"10.3390\/ijerph20032287"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100380","DOI":"10.1016\/j.pecinn.2025.100380","article-title":"Changes in community pharmacy communication \u2013 Towards emotional awareness at the pharmacy counter","volume":"6","author":"Mottelson","year":"2025","journal-title":"PEC Innov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jamda.2006.11.002","article-title":"The consultant pharmacist and the physician in the nursing home: Roles, relationships, and a recipe for success","volume":"8","author":"Levenson","year":"2007","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/10410236.2014.940672","article-title":"Pharmaceutical Role Expansion and Developments in Pharmacist-Physician Communication","volume":"31","author":"Bergman","year":"2016","journal-title":"Heal. Commun."},{"key":"ref_50","first-page":"1","article-title":"Experiences with benzodiazepine use, tapering, and discontinuation: An Internet survey","volume":"12","author":"Macoubrie","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_51","first-page":"100328","article-title":"The role of pharmacists in deprescribing benzodiazepines: A scoping review","volume":"12","author":"Ashkanani","year":"2023","journal-title":"Explor. Res. Clin. Soc. Pharm."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T15:51:39Z","timestamp":1765468299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmacy13060181"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13060181","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}